Phase II Open-Label Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb) in Patients With ErbB2-Positive Stage I-III Breast Cancer.

Trial Profile

Phase II Open-Label Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb) in Patients With ErbB2-Positive Stage I-III Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2014

At a glance

  • Drugs Lapatinib (Primary) ; Carboplatin; Paclitaxel
  • Indications Breast cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 14 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 23 May 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top